The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection

AIDS

Volumn 30, Issue 10, 2016, Pages 1617-1627

  Mehraj, Vikram ^a   Jenabian, Mohammad Ali ^b   Ponte, Rosalie ^a   Lebouché, Bertrand ^a,c   Costiniuk, Cecilia ^a   Thomas, Réjean ^d   Baril, Jean Guy ^e   LeBlanc, Roger ^f   Cox, Joseph ^a   Tremblay, Cécile ^g,h   Routy, Jean Pierre ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Clinique Medicale L Actuel   (Canada)

^e Clinique Médicale Quartier Latin   (Canada)

^f Clinique Médicale OPUS   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CD8 + T cell; early HIV infection; epithelial gut damage; IL 33; kynurenine; microbial translocation; soluble suppression of tumorigenicity 2

Indexed keywords

CD40 LIGAND; CREATININE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; KYNURENINE; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE INJURY; INTESTINE MUCOSA; MALE; MIDDLE AGED; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VIRUS LOAD; YOUNG ADULT; BACTERIAL TRANSLOCATION; BLOOD; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; PATHOLOGY; PLASMA; T LYMPHOCYTE;

ADULT; BACTERIAL TRANSLOCATION; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PLASMA; T-LYMPHOCYTES; VIRAL LOAD; YOUNG ADULT;

EID: 84962385259     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001105     Document Type: Article

References (62)

1. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 2014; 31:31-37.
2. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7:827-840.
3. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8:22.
4. Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol 2016; 17:122-131.
5. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015; 42:566-579.
6. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-490.
7. Talabot-Ayer D, Calo N, Vigne S, Lamacchia C, Gabay C, Palmer G. The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters. J Leukoc Biol 2012; 91:119-125.
8. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115:3B-7B.
9. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282:26369-26380.
10. Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 2015; 42:1005-1019.
11. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and interferon-gamma counterregulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 2015; 43:161-174.
12. Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett 2015; 164:11-17.
13. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-346.
14. Pastorelli L, De Salvo C, Vecchi M, Pizarro TT. The role of IL-33 in gut mucosal inflammation. Mediators Inflamm 2013; 2013:608187.
15. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versushost disease and death. N Engl J Med 2013; 369:529-539.
16. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228-1238.
17. Jenabian MA, El-Far M, Vyboh K, Kema I, Costiniuk CT, Thomas R, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis 2015; 212:355-366.
18. Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in hiv infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis 2016; 62:250-257.
19. Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, et al. Effects of combined CCR5/integrase inhibitorsbased regimen on mucosal immunity in hiv-infected patients naive to antiretroviral therapy: a pilot randomized trial. PLoS Pathog 2016; 12:e1005381.
20. Mehraj V, Textoris J, Ben Amara A, Ghigo E, Raoult D, Capo C, et al. Monocyte responses in the context of Q fever: from a static polarized model to a kinetic model of activation. J Infect Dis 2013; 208:942-951.
21. Jenabian MA, Patel M, Kema I, Kanagaratham C, Radzioch D, Thebault P, et al. Distinct tryptophan catabolism and Th17/ Treg balance in HIV progressors and elite controllers. PLoS One 2013; 8:e78146.
22. Routy JP, Cao W, Mehraj V. Overcoming the challenge of diagnosis of early HIV infection: a stepping stone to optimal patient management. Expert Rev Anti Infect Ther 2015; 13:1189-1193.
23. Riviere E, Ly B, Boudaoud S, Chavez H, Nocturne G, Chanson P, et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjogren syndrome: comparison of different kits. Ann Rheum Dis 2016; 75:633-635.
24. Nygaard U, Vestergaard C, Johansen C, Deleuran M, Hvid M. Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results. Springerplus 2016; 5:33.
25. Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble ST2 from a United States population. Clin Chim Acta 2010; 411:1825-1826.
26. Ho JE, Sritara P, deFilippi CR, Wang TJ. Soluble ST2 testing in the general population. Am J Cardiol 2015; 115:22B-25B.
27. Bergis D, Kassis V, Radeke HH. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark 2016; 16:117-125.
28. Rak GD, Osborne LC, Siracusa MC, Kim BS, Wang K, Bayat A, et al. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J Invest Dermatol 2016; 136:487-496.
29. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1:23-30.
30. Lei Z, Mo Z, Zhu J, Pang X, Zheng X, Wu Z, et al. Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure. Mediators Inflamm 2015; 2015:535938.
31. Miyagaki T, Sugaya M, Yokobayashi H, Kato T, Ohmatsu H, Fujita H, et al. High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection. J Invest Dermatol 2011; 131:794-796.
32. Secemsky EA, Scherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in hiv-infected individuals. JACC Heart Fail 2015; 3:591-599.
33. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-3989.
34. Hartigan-O'Connor DJ, Hirao LA, McCune JM, Dandekar S. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS 2011; 6:221-227.
35. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol 2016; 16:79-89.
36. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8(R) T cell responses. Science 2012; 335:984-989.
37. Jiang Y, An Y, Jiang D, Wu B, Yang Y, Sun D. TNF-alpha regulating interleukin-33 induces acute pancreatic inflammation in rats. Ann Clin Lab Sci 2016; 46:54-59.
38. Ndhlovu ZM, Kamya P, Mewalal N, Kloverpris HN, Nkosi T, Pretorius K, et al. Magnitude and kinetics of CD8R T cell activation during hyperacute HIV infection impact viral set point. Immunity 2015; 43:591-604.
39. Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 2012; 120:3466-3477.
40. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505:509-514.
41. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIVspecific CD8R T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
42. Cao W, Mehraj V, Kaufmann DE, Li T, Routy JP. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc 2016; 19:20697.
43. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001; 98:2778-2783.
44. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6-13.
45. Krebs SJ, Ananworanich J. Immune activation during acute HIV infection and the impact of early antiretroviral therapy. Curr Opin HIV AIDS 2016; 11:163-172.
46. Romero-Sanchez M, Gonzalez-Serna A, Pacheco YM, Ferrando- Martinez S, Machmach K, Garcia-Garcia M, et al. Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 2012; 65:431-438.
47. Adams SD, Delano BA, Helmer KS, Mercer DW. Fasting exacerbates and feeding diminishes LPS-induced liver injury in the rat. Dig Dis Sci 2009; 54:767-773.
48. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS 2015; 29:1263-1265.
49. Freeman ML, Mudd JC, Shive CL, Younes SA, Panigrahi S, Sieg SF, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV Infection. Clin Infect Dis 2016; 62:392-396.
50. Mehraj V, Routy JP. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res 2015; 8:41-48.
51. Routy JP, Mehraj V, Vyboh K, Cao W, Kema I, Jenabian MA. Clinical relevance of kynurenine pathway in HIV/AIDS: an immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev 2015; 17:96-106.
52. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:ra91.
53. Vujkovic-Cvijin I, Swainson LA, Chu SN, Ortiz AM, Santee CA, Petriello A, et al. Gut-resident lactobacillus abundance associates with IDO1 inhibition and Th17 dynamics in SIV-infected macaques. Cell Rep 2015; 13:1589-1597.
54. Jenabian MA, Patel M, Kema I, Vyboh K, Kanagaratham C, Radzioch D, et al. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clin Exp Immunol 2014; 178:102-111.
55. Senhaji N, Kojok K, Darif Y, Fadainia C, Zaid Y. The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol 2015; 6:529.
56. Miller EA, Gopal R, Valdes V, Berger JS, Bhardwaj N, O'Brien MP. Soluble CD40 ligand contributes to dendritic cellmediated T-cell dysfunction in HIV-1 infection. AIDS 2015; 29:1287-1296.
57. Li J, Wang Y, Lin J, Wang D, Wang A, Zhao X, et al. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke 2015; 46:1990-1992.
58. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 2015; 125:3183-3192.
59. Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graftversus- host disease. Sci Transl Med 2015; 7:ra160.
60. Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015; 21:1128-1138.
61. Watanabe T, Sadakane Y, Yagama N, Sakurai T, Ezoe H, Kudo M, et al. Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis. Mucosal Immunol 2016.
62. Okragly AJ, Hamang MJ, Pena EA, Baker HE, Bullock HA, Lucchesi J, et al. Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis. Cytokine 2016; 79:66-73.